Canadian Pilot Programs Initiated with LuViva® Advanced Cervical Scan for Provincial-level Cancer Care Support

OTTAWA--()--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today an initiative for procuring provincial-level support for its LuViva Advanced Cervical Scan. The initiative is based on discussions with women’s healthcare experts across Canada, whose interest has increased after reviewing positive results from two previous evaluations completed in Halifax, Nova Scotia, with Dr. James Bentley and most recently in London, Ontario, with Drs. Robert DiCecco and Monique Bertrand.

“I was impressed with the accuracy of LuViva and that our results so closely mirrored those of Dr. Bentley,” said Dr. DiCecco. “I definitely see a place for LuViva in our clinic to aid in the management of cervical disease, by reducing unnecessary procedures and identifying women at higher risk.”

“The key to making LuViva a success is to engage large government health care systems, where the cost savings and patient benefits are demonstrated on a large scale,” said Gene Cartwright, CEO and President of Guided Therapeutics. “While working with government entities can take time, we believe it is the best path forward for the success for both LuViva and the company.”

Pilot programs are expected to involve up to 80 women in selected provinces and be completed this year, with the first starting this week. Upon successful completion of these evaluations, the company expects that recommendations will be made as to whether to include LuViva in the standard of care, for women at risk of cervical cancer, for the selected provinces. There are approximately 40,000 women in Canada with abnormal Pap tests yearly who would be eligible for a LuViva scan.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and subsequent quarterly reports.

Contacts

Investors:
Cameron Associates
Alison Ziegler, 212-554-5469
or
For Guided Therapeutics
Bill Wells, 770-242-8723 Ext. 241

Release Summary

LuViva® Advanced Cervical Scan Initiated in Canadian Pilot Programs for Provincial-level Cancer Care Support

Contacts

Investors:
Cameron Associates
Alison Ziegler, 212-554-5469
or
For Guided Therapeutics
Bill Wells, 770-242-8723 Ext. 241